Adcendo Reports 30% Response Rate for Sarcoma ADC in Phase 1 Trial

Adcendo ApS reported initial Phase 1 data showing a 30% objective response rate and 85% disease control rate for ADCE-D01 in previously treated advanced soft tissue sarcoma. The results were presented in a late-breaking oral session at the 2026 EORTC-NCI-AACR Symposium in Barcelona.
- ADCE-D01 produced a 30% objective response rate in 27 Q2W-treated, response-evaluable patients.
- The disease control rate was 85%, with all responses ongoing at the data cutoff.
- No patients on the Q2W schedule discontinued treatment because of side effects.
- The ADCElerate1 study is recruiting in the United States and Europe.
- ADCE-D01 has FDA Fast Track and Orphan Drug Designations for soft tissue sarcoma.
Responses reported across 12 sarcoma subtypes
The data came from 27 response-evaluable patients who received ADCE-D01 every two weeks, or Q2W, in the ongoing ADCElerate1 study. Eight patients had a partial response, including five confirmed responses and three that were currently unconfirmed, producing an objective response rate of 30%.
Disease control was reported in 23 of 27 patients, equal to 85%. All responses were ongoing at the data cutoff, while 81%, or 22 of 27 evaluable patients, remained on treatment. Median follow-up was 3.4 months, and the median duration of response had not yet been reached. Adcendo also reported a trend toward improved efficacy at higher dose levels.
The response-evaluable group represented 12 different soft tissue sarcoma subtypes. Across the wider study population, ADCE-D01 had been given to 47 adults with advanced soft tissue sarcoma, covering 17 subtypes. These patients had previously received systemic treatment, including chemotherapy and targeted agents, with a median of two prior lines of therapy and a range of one to four.
Q2W dosing showed a manageable safety profile
The first 18 patients received weekly treatment at doses from 0.5, 3.4 mg/kg. After pharmacokinetic findings indicated that Q2W dosing was more suitable, the next 29 patients received 3.4, 5.5 mg/kg every two weeks. Patients receiving more than 3.4 mg/kg also received preventive granulocyte colony-stimulating factor, or G-CSF.
On the Q2W schedule, the most common treatment-related side effects were low-grade nausea in 59% of patients, infusion-related reactions in 41%, tiredness in 38% and hair loss in 35%. Neutropenia was the most common hematological side effect, occurring in 31% of patients.
Side effects led to dose reductions in 10% of patients on the Q2W schedule, and no patients discontinued treatment because of side effects. Severe neutropenia occurred in 14% of patients who received prophylactic G-CSF, compared with 43% of those who did not, although the G-CSF group received higher doses. The Q2W maximum tolerated dose had not yet been reached. No cases of interstitial lung disease, febrile neutropenia or stomatitis were observed.
Ongoing study will define ADCE-D01’s development path
ADCE-D01 is an antibody-drug conjugate directed at uPARAP, an endocytic receptor that Adcendo says is overexpressed across several cancers of mesenchymal origin. The company describes the drug as a first-in-class ADC and says it combines a uPARAP-binding antibody with a protease-cleavable linker and deruxtecan payload.
ADCElerate1 is a first-in-human Phase I/II, multicenter, open-label dose-escalation and expansion study evaluating ADCE-D01 as a monotherapy in metastatic and/or unresectable soft tissue sarcoma. Its primary objective is to assess safety and tolerability, while secondary objectives include pharmacokinetics and preliminary efficacy. Recruitment on the Q2W schedule is ongoing in the United States and Europe.
ADCE-D01 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration for soft tissue sarcoma. The reported results provide an early clinical signal in a disease with many subtypes and substantial unmet medical need, but the trial remains in Phase 1 and the response data are based on a limited follow-up period.

